癫痫患者中安替比林的药代动力学
Pharmacokinetics of antipyrine in epileptic patients.
作者信息
Rimmer E M, Routledge P A, Tsanaclis L M, Richens A
出版信息
Br J Clin Pharmacol. 1986 May;21(5):511-4. doi: 10.1111/j.1365-2125.1986.tb02833.x.
Abstract
The pharmacokinetics of antipyrine were examined after oral and intravenous administration to 20 epileptic subjects receiving antiepileptic drug therapy. Bioavailability was essentially complete (mean bioavailability 101.2% +/- 14.4 (s.d.] indicating that even in enzyme induced subjects, antipyrine behaves as a restrictively eliminated compound with negligible presystemic elimination in the gut or liver. Of the generally used measures of enzyme induction (oral clearance, oral half-life and intravenous half-life) oral clearance was the most closely related to the intravenous clearance of antipyrine (r = 0.919, P less than 0.001). Oral antipyrine administration is an alternative to intravenous administration in epileptic subjects who are enzyme-induced.
摘要
对20名接受抗癫痫药物治疗的癫痫患者进行口服和静脉注射安替比林后的药代动力学研究。生物利用度基本完全（平均生物利用度101.2%±14.4（标准差）），表明即使在酶诱导的患者中，安替比林也表现为一种消除受限的化合物，在肠道或肝脏中的首过消除可忽略不计。在常用的酶诱导指标（口服清除率、口服半衰期和静脉半衰期）中，口服清除率与安替比林的静脉清除率相关性最强（r = 0.919，P＜0.001）。对于酶诱导的癫痫患者，口服安替比林是静脉注射的一种替代方法。
相似文献
1
Pharmacokinetics of antipyrine in epileptic patients.癫痫患者中安替比林的药代动力学
Br J Clin Pharmacol. 1986 May;21(5):511-4. doi: 10.1111/j.1365-2125.1986.tb02833.x.
2
Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.静脉注射和口服安替比林（非那宗）后的药代动力学与代谢
Arzneimittelforschung. 1982;32(5):575-8.
3
Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.人体中安替比林不同代谢途径的研究。口服与静脉注射给药以及尿液收集时间的影响。
Eur J Clin Pharmacol. 1982;21(5):433-41. doi: 10.1007/BF00542332.
4
A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs.正常受试者及接受酶诱导药物治疗患者中安替比林和利多卡因处置的比较研究。
Br J Clin Pharmacol. 1980 Nov;10(5):491-7. doi: 10.1111/j.1365-2125.1980.tb01794.x.
5
Unaltered metabolism of antipyrine and tolbutamide in fasting man.空腹状态下人体中安替比林和甲苯磺丁脲代谢未受影响。
Clin Pharmacol Ther. 1975 Jun;17(6):650-6. doi: 10.1002/cpt1975176650.
6
Enzyme induction by moricizine: time course and extent in healthy subjects.莫雷西嗪对酶的诱导作用：健康受试者中的时间进程和程度
J Clin Pharmacol. 1994 Feb;34(2):167-75. doi: 10.1002/j.1552-4604.1994.tb03982.x.
7
Elimination of antipyrine from saliva as a measure of metabolism in man.通过测定唾液中安替比林的消除情况来衡量人体新陈代谢。
Clin Pharmacol Ther. 1975 Sep;18(3):249-58. doi: 10.1002/cpt1975183249.
8
Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients.癫痫患者首过代谢增强导致利多卡因口服生物利用度降低。
Br J Clin Pharmacol. 1979 Jul;8(1):21-31. doi: 10.1111/j.1365-2125.1979.tb05904.x.
9
The effect of oral verapamil therapy on antipyrine clearance.口服维拉帕米疗法对安替比林清除率的影响。
Br J Clin Pharmacol. 1986 Nov;22(5):606-9. doi: 10.1111/j.1365-2125.1986.tb02942.x.
10
The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.正常受试者及慢性肝病患者中安替比林和吲哚菁绿的清除率
Clin Pharmacol Ther. 1976 Jul;20(1):81-9. doi: 10.1002/cpt197620181.
引用本文的文献
1
Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.在接受联合治疗的患者中，去除个别抗癫痫药物对安替比林动力学的影响。
Br J Clin Pharmacol. 1988 Sep;26(3):253-9. doi: 10.1111/j.1365-2125.1988.tb05274.x.
2
Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.利用非那宗（安替比林）及其代谢物对存在肝脏疾病时的肝功能进行定量分析。
Clin Pharmacokinet. 1991 Jan;20(1):50-65. doi: 10.2165/00003088-199120010-00004.
3
Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.健康受试者中奥卡西平（每日600毫克）缺乏酶诱导作用。
Br J Clin Pharmacol. 1991 Jan;31(1):65-71. doi: 10.1111/j.1365-2125.1991.tb03858.x.
本文引用的文献
1
A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs.正常受试者及接受酶诱导药物治疗患者中安替比林和利多卡因处置的比较研究。
Br J Clin Pharmacol. 1980 Nov;10(5):491-7. doi: 10.1111/j.1365-2125.1980.tb01794.x.
2
Effect of rifampicin on metoprolol and antipyrine kinetics.利福平对美托洛尔和安替比林药代动力学的影响。
Br J Clin Pharmacol. 1982 Mar;13(3):387-91. doi: 10.1111/j.1365-2125.1982.tb01390.x.
3
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.抗惊厥药物对癫痫患者相对酶诱导特性的比较研究。
Br J Clin Pharmacol. 1984 Sep;18(3):401-10. doi: 10.1111/j.1365-2125.1984.tb02482.x.
4
Assessment of the drug metabolism capacity of the liver.肝脏药物代谢能力的评估。
Br J Clin Pharmacol. 1982 Nov;14(5):631-51. doi: 10.1111/j.1365-2125.1982.tb04950.x.
5
Effects of physical stress on the disposition of drugs eliminated by the liver in man.体力应激对人体肝脏消除药物处置的影响。
J Pharmacol Exp Ther. 1974 Jan;188(1):1-7.
6
Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.气相色谱法评估年轻健康志愿者中非那宗血浆半衰期的重现性。
Eur J Clin Pharmacol. 1974 Aug 23;7(5):381-5. doi: 10.1007/BF00558211.
7
Salivary antipyrine half-life: a useful measure of hepatic drug metabolism.唾液中安替比林半衰期：肝脏药物代谢的一项有用指标。
Br J Clin Pharmacol. 1976 Oct;3(5):945-6. doi: 10.1111/j.1365-2125.1976.tb00656.x.
8
The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.苯巴比妥给药前后人体肝脏体积、安替比林清除率和吲哚菁绿清除率之间的关系。
Br J Clin Pharmacol. 1976 Oct;3(5):907-13. doi: 10.1111/j.1365-2125.1976.tb00646.x.
9
Assessment of antipyrine kinetics by measurement in saliva.通过唾液测量评估安替比林动力学。
Br J Clin Pharmacol. 1976 Apr;3(2):321-5. doi: 10.1111/j.1365-2125.1976.tb00610.x.
10
Effect of surgery under general anaesthesia on antipyrine clearance.全身麻醉下手术对安替比林清除率的影响。
Br J Clin Pharmacol. 1978 Dec;6(6):505-13. doi: 10.1111/j.1365-2125.1978.tb00874.x.
Zotero 插件